27030 Extended safety analysis of baricitinib 2-mg in adult patients with atopic dermatitis: An integrated analysis from 8 randomized clinical trials

King, Brett; Maari, Catherine; Lain, Edward; Silverberg, Jonathan I.; Issa, Maher; Holzwarth, Katrin; Brinker, Dennis; Cardillo, Tracy; Nunes, Fabio P.; Simpson, Eric L.

doi:10.1016/j.jaad.2021.06.525

Our system is currently under heavy load due to increased usage. We're actively working on upgrades to improve performance. Thank you for your patience.

Journal of the American Academy of Dermatology

2021

DOI: 10.1016/j.jaad.2021.06.525

|View full text |Cite

27030 Extended safety analysis of baricitinib 2-mg in adult patients with atopic dermatitis: An integrated analysis from 8 randomized clinical trials

Brett King¹,

Catherine Maari²,

Edward Lain³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Safety considerations of systemic Janus kinase inhibitors in atopic dermatitis applications

Chang

Huang

2021

The Journal of Dermatology

View full text Add to dashboard Cite

Janus kinase (JAK) inhibitors are emerging treatments for atopic dermatitis (AD). Due to this novel role as a therapeutic option for patients with AD, we aimed to review current evidence on the pathophysiology and the safety and adverse effects (AEs) of oral JAK inhibitors for the treatment of AD utilizing the key terms atopic dermatitis, JAK inhibitors, and adverse effect or event. Our study indicated that oral JAK inhibitors have a moderate safety profile for use in AD in several reviews and phase II or III clinical trials. Headaches, nausea, and nasopharyngitis are the most commonly reported systemic AEs. Furthermore, acne, herpes simplex, herpes zoster, and eczema herpeticum are the most commonly recorded dermatological AEs. Current evidence indicates JAK inhibitors may also have less association with some of the serious AEs, although there is potential for increased risk of asthma, acute pancreatitis, neutropenia, and thrombocytopenia. Whereas data remain limited for the long‐term safety of JAK inhibitor use in patients with AD, many ongoing clinical trials have promising preliminary results.

show abstract

Safety considerations of systemic Janus kinase inhibitors in atopic dermatitis applications

Chang

Huang

2021

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

27030 Extended safety analysis of baricitinib 2-mg in adult patients with atopic dermatitis: An integrated analysis from 8 randomized clinical trials

Cited by 1 publication

References 0 publications

Safety considerations of systemic Janus kinase inhibitors in atopic dermatitis applications

Safety considerations of systemic Janus kinase inhibitors in atopic dermatitis applications

Contact Info

Product

Resources

About